otcbargains undervalued stock board

[Potse]

dickmilde...regarding IVRO......

The principals are 70+ years old... probably tired of getting up in the morning to go to work
So whats in the future for this little company? Take a look at what they are looking forward to... A hat tip from OECD. I went to the OECD web site to see what they do and why they might be important. Best I can tell OECD does absolutely nothing that anyone else would be interested in. They are a think tank the makes recommendations on a 10 year interval to governments. OECD puts out a position paper describing laws governments should consider so that their populations are content.

"Policymakers need to deploy broad-based reform plans that incorporate monetary, fiscal, and structural policies to stimulate persistently weak demand, re-launch productivity growth, create jobs and build a more inclusive global economy, according to the OECD’s annual Going for Growth report.
www.oecd.org

Anyway... unless something else is going on it doesn't look like there is any reason to invest here. I will admit that .03 cents a share on the balance sheet for a stock trading under .02 is interesting. But the real question is... "What's next?"... and "When?"

Generally speaking, I view IVRO as a reasonably attractive value/growth investment. The company may have reached a pivot point where its profitability going forward could be noticeably improved versus its past/recent performance. The stock is very underfollowed and is capable of explosive moves if even mild buying pressure hits it.

The language in its last two earnings press releases suggests that whatever operating cost improvements/savings the company has made over the last year or two will positively impact the company for awhile. From the FY 2014 press release.....

IVRO CEO & President, W. Richard Ulmer, said "FY 2014 was a year of re-positioning for IVRO. Relocating the company proved exciting since we saw immediate cost savings and fully expect they will continue for several years.

The statement by Ulmer in the FY 2015 press release suggests that once OECD adoption is complete the company will increase its marketing efforts (which should translate into increased revenue)......

Next, our 2014 company relocation along with several new cost saving measures provided important cash growth in 2015. So now looking forward, we believe the pieces will be in place to support promotion of Ocular Irritection should it receive full OECD Regulatory adoption in the near future.

I disagree with your comment that the OECD "does absolutely nothing that anyone else would be interested in". While the policies/guidelines that the OECD implement/endorses are not binding for its 34-member nations (soft law versus hard law), it is still an agency/organization that can have a significant influence on a number of things.

Res Pharma is a privately-held Italian company that has an equity position in IVRO (http://www.respharma.com/index.asp). Both Res Pharma and IVRO appear to think that obtaining full regulatory adoption of Ocular Irritection is an important move for IVRO. They would not have spent 3+ years on the clinical/validation trials for the product (plus all of the years spent working the submission through the regulatory process) if they didn't believe it was strategically important.

The chances that Irritection will become part of the new OECD international test guidelines look pretty good, based on the last available public information (April 2015) that Integra (a Res Pharma subsidiary) posted on its website.....

http://caoanalysis.com/uploadedImages/OECD%20Ocular%20Irritection%20Assay%20Acceptance.pdf